MICA · CARE LEARNING NOTES
Observe, keep care safe and communicate
IV iron involves more than correcting low haemoglobin: deficiency must be documented, the product identified and tolerability monitored. Ferric carboxymaltose has a particular hypophosphataemia risk that may become apparent after treatment.
Check the prescribed iron complex
The reference is Ferinject 50 mg iron/mL ferric carboxymaltose dispersion for injection or infusion, Vifor, UK SmPC. Check name, complex, iron concentration, presentation and prescription. Other IV irons have different characteristics: do not transfer their technical instructions by analogy. The UK document does not establish the product marketed in Algeria; pharmacy must verify the local reference and instructions.
[1]Check the indication and risk factors
Ensure that iron deficiency is supported by laboratory testing and that the prescriber has considered overload or another cause of anaemia. Check previous parenteral iron reactions, allergies, severe asthma, infection and recent administrations. Report hypophosphataemia risks, including malabsorption or vitamin D deficiency, and check the prescribed investigation plan for repeated or prolonged treatment.
[1][2]Observe the patient and venous site
Arrange trained staff, emergency equipment and post-administration observation according to the SmPC and validated protocol. Previous uneventful exposure does not exclude anaphylaxis. Faintness, dyspnoea, chest tightness or hypotension require immediate interruption of the suspected product and emergency escalation. Local pain, swelling or discolouration suggest extravasation: interrupt administration and follow the protocol with prompt assessment, as brown pigmentation may persist.
[1]With ferric carboxymaltose, persistent or worsening fatigue, muscle or bone pain may warrant medical investigation for hypophosphataemia, particularly after repeated administration. Do not automatically attribute these symptoms to the original anaemia. Laboratory monitoring is individualised; site observation also helps prevent extravasation-related skin staining.
- Provide contact instructions for delayed symptoms before discharge.
Recognise a delayed problem
Explain that worsening fatigue, muscle or bone pain after treatment must be reported. These findings may be wrongly attributed to anaemia when hypophosphataemia is possible. The prescriber decides on phosphate testing and treatment reassessment. Record product, batch, administrations, symptoms and handover; do not independently recommend supplements or another session.
[2]A learning situation
FICTIONAL SITUATION · REFLECTION WITHOUT A SCORE
Fictional situation: after several sessions, a patient reports worsening fatigue and bone pain despite improved haemoglobin.
What should be communicated to the prescriber?
References and scope
- Ferinject 50 mg iron/mL dispersion for injection/infusion — SmPC (UK) ↗
- Ferric carboxymaltose (Ferinject): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures ↗
Original documentary teaching summary for adult care. Procedures and medicines depend on professional competence, prescription and institutional procedures. International references do not establish an Algerian protocol. Independent human scientific review remains to be confirmed.